Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(n-(dicyclopropylmethyl)amino)oxazoline
2. 2-(n-(dicyclopropylmethyl)amino)oxazoline Phosphate Salt
3. Hyperium
4. Oxaminozoline
5. Rilmenidine
6. S 3341
7. S 3341 3
8. S-3341
9. S-3341-3
10. S3341
11. S33413
1. 85409-38-7
2. Rilmenidine Dihydrogen Phosphate
3. Rilmenidine (phosphate)
4. S 3341-3
5. 2-oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, Phosphate (1:1)
6. N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine;phosphoric Acid
7. 59qd64q32m
8. N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine Phosphate
9. Rilmenidinephosphate
10. Einecs 287-106-2
11. Unii-59qd64q32m
12. 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine Phosphate (1:1)
13. 2-oxazolamine, 4,5-dihydro-n-(dicyclopropylmethyl)-, Phosphate (1:1)
14. (dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium Dihydrogen Phosphate
15. Schembl1231349
16. Dtxsid50234616
17. Rilmenidine For System Suitability
18. Rilmenidine Phosphate [mi]
19. Bcp13443
20. Mfcd00875846
21. N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; Phosphoric Acid
22. Rilmenidine Hydrogen Phosphate
23. S7548
24. Rilmenidine Phosphate [mart.]
25. Akos015900521
26. N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine,phosphoric Acid
27. Rilmenidine Phosphate [who-dd]
28. Ccg-267224
29. Hy-100490b
30. As-15125
31. Cs-0020190
32. Ft-0656776
33. A14256
34. S-3341
35. 409r387
36. A841323
37. S-3341-3
38. W-104082
39. Q27261715
40. Rilmenidine Dihydrogen Phosphate [ep Monograph]
41. (5-methylpyridin-2-yl)piperidin-4-yl-aminedihydrochloride
42. 2-((dicyclopropylmethyl)amino)-2-oxazoline Phosphate
43. Dicyclopropylmethyl-(4,5-dihydrooxazol-2-yl)ammonium Phosphate
Molecular Weight | 278.24 g/mol |
---|---|
Molecular Formula | C10H19N2O5P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 278.10315871 g/mol |
Monoisotopic Mass | 278.10315871 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?